Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients - 21/08/11
Résumé |
Background |
The TIMI ST-elevation myocardial infarction (STEMI) score was developed and validated in a randomized controlled trial population. We sought to assess its accuracy in a community-based cohort of elderly patients hospitalized with STEMI.
Methods |
We evaluated the TIMI STEMI score in 47882 patients aged ≥65 years hospitalized with STEMI in US hospitals from 1994 to 1996. We assessed TIMI STEMI score discrimination and calibration for 30-day mortality and compared observed and published TIMI mortality rates.
Results |
The cohort's median TIMI score was 6 (25th-75th percentile 4, 8). Thirty-day mortality rates were higher among patients with higher TIMI scores (TIMI score 2: 4.4% vs TIMI score >8: 35.6%, P < .0001 for trend). However, the TIMI score provided only modest discrimination (c = 0.67) and calibration (goodness-of-fit P < .0001). Mortality rates for TIMI scores differed between patients who did and did not receive reperfusion therapy (P < .0001 for TIMI score × reperfusion therapy interaction). Thirty-day mortality rates in the cohort were higher than published TIMI estimates (P = .001; eg, TIMI score 2: 4.4% cohort vs 2.2% published rate).
Conclusions |
The TIMI score provided modest prognostic discrimination and calibration among elderly patients with STEMI. Our findings highlight the difficulties in applying risk scores developed in randomized controlled trial cohorts to elderly patients.
Le texte complet de cet article est disponible en PDF.Plan
| Saif Rathore was supported by NIH/National Institute of General Medical Sciences Medical Scientist Training Grant GM07205. |
Vol 150 - N° 3
P. 402-410 - septembre 2005 Retour au numéro
Article précédent
- Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non–ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study
- Mario Leoncini, Anna Toso, Mauro Maioli, Francesco Bellandi, Toni Badia, Alessandro Politi, Stefano De Servi, Roberto Piero Dabizzi
- A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: Rationale and initial results of the HIJAMI Registry
- Hiroshi Kasanuki, Takashi Honda, Kazuo Haze, Tetsuya Sumiyoshi, Toshinobu Horie, Masahiro Yagi, Jun-ichi Yamaguchi, Yasuhiro Ishii, Shin-ya Fujii, Michitaka Nagashima, Hisayuki Okada, Hiroshi Koganei, Ryo Koyanagi, Yukio Tsurumi, Hirotaka Kimura, Hiroshi Ogawa, for the HIJAMI Investigators Tokyo, Kumamoto, Osaka, and Saitama, Japan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?